Marti Appoints President, Cankut Durgun, to Additional Role of Chief Operating Officer
ISTANBUL--(BUSINESS WIRE)--Marti Technologies, Inc. ('Marti' or the 'Company') (NYSE American: MRT), Türkiye's leading mobility super app, announced today the appointment of Cankut Durgun, the Company's Co-founder and President, to the additional role of Chief Operating Officer, effective as of June 12, 2025.
In this expanded role, Mr. Durgun will continue to lead Marti's strategic initiatives as President, while also assuming responsibility for overseeing the Company's day-to-day operations. His operational focus will include driving execution across Marti's high-growth ride-hailing operations and its established two-wheeled electric vehicle operations.
'I'm excited to further contribute to Marti's operational excellence as we scale to meet the growing mobility demand in Türkiye,' Mr. Durgun shared. 'We remain committed to delivering safe, affordable, and efficient transportation solutions for millions of users.'
Mr. Durgun has served as Marti's President since co-founding the Company in 2018. Prior to co-founding Marti, he was co-founder and general partner of venture capital firms, Aslanoba Capital and Romulus Capital. Mr. Durgun earned his Bachelor of Science degree in Economics and Management Science from Massachusetts Institute of Technology and his Master of Business Administration from Stanford University.
About Marti:
Founded in 2018, Marti is Türkiye's leading mobility app, offering multiple transportation services to its riders. Marti operates a ride-hailing service that matches riders with car, motorcycle, and taxi drivers, and operates a large fleet of rental e-mopeds, e-bikes, and e-scooters. All of Marti's offerings are serviced by proprietary software systems and IoT infrastructure. For more information, visit www.marti.tech.
Cautionary Note Regarding Forward-Looking Statements:
Certain statements made in this press release constitute forward-looking statements within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements related to the Chief Operating Officer appointment and the Company's expectation with respect to its future performance and the timing of occurrence related to any of the foregoing. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including the risks discussed in the Company's filings with the SEC, including the Company's Annual Report on Form 20-F. The Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of future events, new information or otherwise, except as required by law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
32 minutes ago
- Business Wire
Enveric Biosciences Announces Participation in 2025 BIO International Convention
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Enveric Biosciences (NASDAQ: ENVB) ('Enveric' or the 'Company'), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders, today announced that the company is participating in the BIO International Convention being held June 16-19, 2025, in Boston, Massachusetts. During the conference, CEO and Director of Enveric, Joseph Tucker, Ph.D., will conduct one-on-one meetings with registered investors and potential partners, showcasing the company's business and development strategy, recent corporate achievements, and anticipated milestones. About Enveric Biosciences Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders. Leveraging its unique discovery and development Psybrary™ platform, which houses proprietary information on the use and development of existing and novel molecules for specific mental health indications, Enveric seeks to develop a robust intellectual property portfolio of novel drug candidates. Enveric's lead molecule, EB-003, is a potential first-in-class neuroplastogen designed to promote neuroplasticity, without inducing hallucinations, in patients suffering from difficult-to-address mental health disorders. Enveric is focused on advancing EB-003 towards clinical trials for the treatment of neuropsychiatric disorders while out-licensing other novel, patented Psybrary™ platform drug candidates to third-party licensees advancing non-competitive market strategies for patient care. Enveric is headquartered in Naples, FL with offices in Cambridge, MA and Calgary, AB Canada. For more information, please visit Forward-Looking Statements This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as "plans," "expects" or "does not expect," "proposes," "budgets," "explores," "schedules," "seeks," "estimates," "forecasts," "intends," "anticipates" or "does not anticipate," or "believes," or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: finalize and submit its IND filing to the U.S. Food and Drug Administration; carry out successful clinical programs; achieve the value creation contemplated by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary governmental approvals to market potential products; obtain future funding for product development and working capital on commercially reasonable terms; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors; hire and retain key executives and scientists; secure and enforce legal rights related to Enveric's products, including patent protection; identify and pursue alternative routes to capture value from its research and development pipeline assets; continue as a going concern; and manage its future growth effectively. A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric's filings with the Securities and Exchange Commission, including Enveric's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Business Wire
36 minutes ago
- Business Wire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma
NEW YORK--(BUSINESS WIRE)-- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Zenas BioPharma, Inc. ('Zenas' or the 'Company') (NASDAQ: ZBIO) and reminds investors of the June 16, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Zenas BioPharma materially overstated the amount of time it would be able to fund its operations using existing cash and expected net proceeds from the IPO; and (2) as a result, defendants' public statements were materially false and misleading at all relevant times and negligently prepared. When the true details entered the market, the lawsuit claims that investors suffered damages. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Zenas' conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Zenas BioPharma class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
Business Wire
36 minutes ago
- Business Wire
Pondurance Ranked #8 Top Cybersecurity Company of 2025
WASHINGTON--(BUSINESS WIRE)--Pondurance, the leading provider of managed detection and response (MDR) cybersecurity services designed to minimize breach risks, today announced that they were ranked #8 in the recently released Top 25 Cybersecurity Companies of 2025 by Software Report. This coincides with Pondurance launching a new website making it easier for organizations to navigate their journey for selecting an optimal managed security solution. In addition to its multiple award-winning managed detection and response (MDR) service, Pondurance also provides best-in-class digital forensics and incident response (DFIR) services, exposure and vulnerability services, and an extensive array of cybersecurity and compliance professional services offerings. '2025 has been a pivotal year for Pondurance. We've innovated our risk-based MDR platform while maintaining relentless focus on providing the kind of personalized service unavailable from the big-box cybersecurity players,' said Doug Howard, CEO and president of Pondurance. 'By addressing everpresent breach risks and cybersecurity threats for organizations with regulated data, Pondurance has cracked the code for rapid growth and operational excellence in a confusing cybersecurity market.' Pondurance is unique in having developed a risk-based, cloud-native platform and using that specifically to provide managed security services for organizations that need to rely on a trusted party for its security technology and operational needs. By combining new exposure & vulnerability capabilities, a next-generation managed SIEM, and a best-in-class MDR service, with its US-based, 24/7 security operations center (SOC), incident response (IR), and security services teams, Pondurance stands alone in the breach risk protection it offers its customers. The award-winning Pondurance MDR service is now available for a limited time 30-day free trial for new qualified customers. This comes complete with a next-generation managed SIEM and an entirely U.S.-based 24/7 security operations center (SOC). To learn more about this offer, visit Additional Resources Join the conversation with Pondurance on Linkedin, YouTube, and Bluesky To learn more about the Pondurance MDR, incident response and cyber advisory services, visit Interested in becoming a Pondurance Partner? Apply today About Pondurance Pondurance is the only provider of managed detection and response (MDR) services specifically engineered to minimize breach risks. As a full-service provider of incident response (DFIR), MDR, exposure management, and cybersecurity advisory and compliance services, Pondurance protects mid-sized organizations from data breach before, during and after they occur. Organizations entrusted with consumer PHI and PII rely on Pondurance to provide a unified platform and outsourced security operations center (SOC) service.
